New quarterly report expected Apr 21, 2026. Report will refresh after results.
O
Bank OZK
OZK · Financial Services
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Cheap Funding, Expensive Loan Book, One Man's Judgment at Stake
The market is debating credit cycle duration, but the more important and unanswered question is whether RESG's pristine historical loss record reflects a genuinely superior underwriting process or simply the longest benign commercial real estate cycle in modern history — a distinction that only becomes visible in the data we're waiting for. The talent retention risk inside RESG during an active workout is almost entirely absent from the bull case.
Flowly Score
Apr 16 Close
+9%$47.79
Fair Value
$52.00
42
Below Averageat $47.79
Business Strength5/10
A genuinely differentiated specialty lending franchise — RESG's process power is real — but concentration in a single business unit and a ROIC collapse to near-zero in 2025 mean the moat is being stress-tested, not proven. Owner-operator alignment is exceptional; the governance structure amplifies whatever the cycle reveals about his credit judgment.
Financial Resilience5/10
Multi-year OCF exceeding net income confirms the earnings are real, and the ACL build to over twice its prior level shows deliberate fortress-building rather than denial. The Q4 cash flow zeroing is a single-quarter anomaly, but capital conservation mode replacing buyback aggression signals management hedging against scenarios they won't discuss publicly.
Growth & Trajectory4/10
The 2021–2023 earnings arc was a rate-cycle gift, not organic momentum, and the business has now returned to flat with management explicitly guiding 2026 as another transition year. Fee income diversification is the right strategic move but won't register materially until 2027 at the earliest — the growth engine is idling, waiting for a CRE cycle that may or may not cooperate on schedule.
Valuation5/10at $44.76
Seven times earnings with management repurchasing stock below tangible book value is a setup that historically rewards patient capital — the franchise has demonstrably earned well above its cost of capital through most of the cycle. The discount is justified but not irrational; normalized earnings recovery makes the price look cheap in hindsight, while further credit deterioration makes it look like a trap.
Risk4/10
The cascade scenario — construction loan defaults compounding simultaneously with elevated funding costs, capital depletion, and regulatory scrutiny — is not theoretical; it is the active scenario management is navigating in real time across office, life sciences, and high-density multifamily. Key-man risk and RESG talent retention during the workout period are the underappreciated amplifiers that no multiple captures.
The investment case is a bet on mean reversion in a franchise that has historically earned well above its cost of capital, purchased at a multiple that assumes the worst without pricing in any recovery. The funding engine — sticky retail deposits from the Southeast at below-market rates — is structurally intact and genuinely valuable; it's the asset side that carries the uncertainty. When the price is this far below tangible book value and management is buying back stock aggressively, the market is either pricing in permanent impairment or offering a genuine margin of safety. Both are defensible interpretations of the same facts. The business is heading toward a 2027 inflection or a prolonged workout, with almost no middle path. Management's guidance framework — 2026 as a transition year, 2027 as the recovery year — requires faith in the CRE cycle turning on a predictable timeline and RESG sponsors continuing to contribute equity support at the current rate. The fee income diversification push into mortgage, wealth management, and treasury services is the right long-term move, but it's a rounding error against RESG in the near term and serves mainly as evidence that management recognizes the concentration problem even if they won't say so directly. The single biggest specific risk is not gradual credit deterioration — the ACL buffer is substantial and the capital ratios are strengthening — but rather a loss of key RESG underwriters during the stress period. The process power that defines this franchise lives entirely in people: relationships with sponsors, institutional memory about what separates a recoverable credit from a permanent impairment, and the judgment to work through complex amendments under pressure. If that team fractures while navigating the current workout — senior talent leaving for competitors, headhunted by distressed debt funds, or simply burned out — the moat evaporates before the credit cycle resolves, and the franchise is worth meaningfully less than any normalized earnings model suggests.